Literature DB >> 21477952

Decreased striatal dopamine transporters in codeine-containing cough syrup abusers.

Haifeng Hou1, Shugui Yin, Shaowei Jia, Shu Hu, Taotao Sun, Qing Chen, Rong Fan.   

Abstract

BACKGROUND: In recent years, codeine-containing cough syrups (CCS) have been reported as substances of abuse, especially in adolescents. Chronic CCS abuse can induce physical and psychological dependence. However, the potential brain impairment caused by chronic CCS abuse has not been reported previously. The present study was designed to determine if the striatal dopamine transporter (DAT) levels measured by (99m)Tc-TRODAT-1 single photon emission computed tomography (SPECT) brain scans were altered in CCS-dependent subjects and to explore the CCS-caused brain impairment.
METHODS: SPECT brain scans were acquired on 22 CCS-dependent subjects and 27 healthy age matched controls. The volume (V) and weight (W) of bilateral corpus striatum as well as the (99m)Tc-TRODAT-1 uptake ratio of corpus striatum/the whole brain (Ra) were calculated using mathematical models.
RESULTS: It was displayed that DAT availability of striatum was significantly decreased and the V, W and Ra were greatly reduced in the CCS-dependent group compared to controls (for each comparison p<0.01).
CONCLUSION: Taken together, these results suggest that chronic CCS abuse may cause serious damage to the brain and the neuroimaging findings further illustrate the mechanism of CCS dependence.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477952     DOI: 10.1016/j.drugalcdep.2011.03.011

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  9 in total

1.  Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies.

Authors:  Felicia Kamp; Lisa Proebstl; Nora Penzel; Kristina Adorjan; Andrej Ilankovic; Oliver Pogarell; Gabi Koller; Michael Soyka; Peter Falkai; Nikolaos Koutsouleris; Joseph Kambeitz
Journal:  Neuropsychopharmacology       Date:  2018-08-27       Impact factor: 7.853

2.  Abnormal white matter integrity in chronic users of codeine-containing cough syrups: a tract-based spatial statistics study.

Authors:  Y-W Qiu; H-H Su; X-F Lv; G-H Jiang
Journal:  AJNR Am J Neuroradiol       Date:  2014-08-07       Impact factor: 3.825

3.  Cough, codeine and confusion.

Authors:  David O Reilly; Mathew Thomas; Edina Moylett
Journal:  BMJ Case Rep       Date:  2015-12-23

4.  Reduced striatal dopamine transporters in people with internet addiction disorder.

Authors:  Haifeng Hou; Shaowe Jia; Shu Hu; Rong Fan; Wen Sun; Taotao Sun; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-13

5.  The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.

Authors:  E Zoons; M A J Tijssen; Y E M Dreissen; J D Speelman; M Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-17       Impact factor: 9.236

6.  Reduced regional homogeneity in bilateral frontostriatal system relates to higher impulsivity behavior in codeine-containing cough syrups dependent individuals.

Authors:  Yingwei Qiu; Xiaofei Lv; Huanhuan Su; Guihua Jiang; Junzhang Tian; Fuzhen Zhuo; Lujun Han; Xuelin Zhang
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

Review 7.  Antitussives and substance abuse.

Authors:  Jarrett M Burns; Edward W Boyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-06

Review 8.  A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy.

Authors:  Evelyn Hearne; Jean-Paul Cornelius Grund; Marie Claire Van Hout; Jim McVeigh
Journal:  Harm Reduct J       Date:  2016-04-19

9.  Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.

Authors:  Stefania Chiappini; Fabrizio Schifano; John Martin Corkery; Amira Guirguis
Journal:  J Psychopharmacol       Date:  2021-01-10       Impact factor: 4.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.